- pregnancy or lactation - absolute neutrophil count less than 1.5 x 109/l - hepatic transaminases ast or alt greater than 5 times normal values - platelet count less than 50,000 per mm3 - solid organ or hematopoietic stem cell transplant patients - patients treated with immunosuppressants or immunomodulators - use of oral corticosteroids chronically at doses greater than 10 mg prednisone equivalent per day for a non-covid-19 related condition. - uncontrolled autoimmune disease - patients with active, suspected or known, uncontrolled systemic bacterial, viral (excluding covid-19) or fungal infections - hypersensitivity to anakinra and/or ruxolitinib and their excipients - vaccinations with live attenuated vaccines in the month prior to inclusion - patients with severe pre-existing uncontrolled organ dysfunction (heart, liver or kidney failure) - persons deprived of liberty by judicial or administrative decision or major persons under a legal protection measure. - person in exclusion period of another research protocol for sars-cov-2 infection. - person not mastering enough french understanding and reading to be able to consent to participate in the study. - persons under psychiatric care pursuant to articles a3112-1 and l3113-1 who are not covered by the provisions of article l1121-8 - every condition which, according to investigator, might increase and compromise the person security in case of study participation or might interfere with research results.

- pregnancy or lactation - absolute neutrophil count less than 1.5 x 109/l - hepatic transaminases ast or alt greater than 5 times normal values - platelet count less than 50,000 per mm3 - solid organ or hematopoietic stem cell transplant patients - patients treated with immunosuppressants or immunomodulators - use of oral corticosteroids chronically at doses greater than 10 mg prednisone equivalent per day for a non-covid-19 related condition. - uncontrolled autoimmune disease - patients with active, suspected or known, uncontrolled systemic bacterial, viral (excluding covid-19) or fungal infections - hypersensitivity to anakinra and/or ruxolitinib and their excipients - vaccinations with live attenuated vaccines in the month prior to inclusion - patients with severe pre-existing uncontrolled organ dysfunction (heart, liver or kidney failure) - persons deprived of liberty by judicial or administrative decision or major persons under a legal protection measure. - person in exclusion period of another research protocol for sars-cov-2 infection. - person not mastering enough french understanding and reading to be able to consent to participate in the study. - persons under psychiatric care pursuant to articles a3112-1 and l3113-1 who are not covered by the provisions of article l1121-8 - every condition which, according to investigator, might increase and compromise the person security in case of study participation or might interfere with research results.